Comments for TB R&D Matters Blog http://www.newtbdrugs.org/blog Working Towards a Faster Cure for Tuberculosis Mon, 21 Jan 2013 06:39:43 +0000 hourly 1 http://wordpress.org/?v=3.3.1 Comment on TB R&D Weekly Update: Podcast Interview with Armand Van Deun by TB STUDY GROUP (TSG) http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-armand-van-deun/comment-page-1/#comment-7075 TB STUDY GROUP (TSG) Mon, 21 Jan 2013 06:39:43 +0000 http://blog.newtbdrugs.org/?p=2725#comment-7075 Short, highly effective and inexpensive standardized treatment for MDT-TB Tuberculosis is a major public health problem in Bangladesh as well as the MDR-TB. Bangladesh is a resource constrains country. MDR-TB treatment facilities are inadequate. A long ques for MDR-TB patients are seen each year; WHO recommended conventional treatment needs 18 months to 24 months to be completed. Short, highly effective and inexpensive standardized treatment for MDT-TB requires only 9 (nine) months in some case few more months are necessary with modification of combination of second and first line drugs from conventional treatment. The research results has shown that treatment outcome is as like as the treatment outcome of first line drugs (for the Tuberculosis). The result is encouraging and it definitely improves compliance of MDT-TB patients. The compliance of standardized MDR-TB drugs is a big issue due to its long duration. The short, highly effective and inexpensive standardized MDR-TB treatment will improve patient’s compliance. Thus a patient benefit is there. TB STUDY GROUP (TSG) congratulates Armand Van Deun for his initiative to carry out such a research with short, highly effective and inexpensive standardized MDR-TB treatment. TSG also congratulates him for receiving the Kochon prize for 2010. Van Deon is a great friend of TB patients of Bangladesh. TSG sincerely appreciates his effort in the field of Tuberculosis. Dr. Ahmed Parvez Zabeen Chief Executive Office TB STUDY GROUP (TSG) Short, highly effective and inexpensive standardized treatment for MDT-TB

Tuberculosis is a major public health problem in Bangladesh as well as the MDR-TB. Bangladesh is a resource constrains country. MDR-TB treatment facilities are inadequate. A long ques for MDR-TB patients are seen each year; WHO recommended conventional treatment needs 18 months to 24 months to be completed.

Short, highly effective and inexpensive standardized treatment for MDT-TB requires only 9 (nine) months in some case few more months are necessary with modification of combination of second and first line drugs from conventional treatment.

The research results has shown that treatment outcome is as like as the treatment outcome of first line drugs (for the Tuberculosis). The result is encouraging and it definitely improves compliance of MDT-TB patients. The compliance of standardized MDR-TB drugs is a big issue due to its long duration. The short, highly effective and inexpensive standardized MDR-TB treatment will improve patient’s compliance. Thus a patient benefit is there.

TB STUDY GROUP (TSG) congratulates Armand Van Deun for his initiative to carry out such a research with short, highly effective and inexpensive standardized MDR-TB treatment.

TSG also congratulates him for receiving the Kochon prize for 2010.
Van Deon is a great friend of TB patients of Bangladesh. TSG sincerely appreciates his effort in the field of Tuberculosis.

Dr. Ahmed Parvez Zabeen
Chief Executive Office
TB STUDY GROUP (TSG)

]]> Comment on TB R&D Weekly Update: Podcast Interview with Armand Van Deun by TB STUDY GROUP (TSG) http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-armand-van-deun/comment-page-1/#comment-7070 TB STUDY GROUP (TSG) Sun, 20 Jan 2013 17:46:46 +0000 http://blog.newtbdrugs.org/?p=2725#comment-7070 Short, highly effective and inexpensive standardized treatment for MDT-TB Tuberculosis is a major public health problem in Bangladesh as well as the MDR-TB. Bangladesh is a resource constrains country. MDR-TB treatment facilities are inadequate. A long ques for MDR-TB patients are seen each year; WHO recommended conventional treatment needs 18 months to 24 months to be completed. Short, highly effective and inexpensive standardized treatment for MDT-TB requires only 9 (nine) months in some case few more months are necessary with modification of combination of second and first line drugs from conventional treatment. The research results has shown that treatment outcome is as like as the treatment outcome of first line drugs (for the Tuberculosis). The result is encouraging and it definitely improves compliance of MDT-TB patients. The compliance of standardized MDR-TB drugs is a big issue due to its long duration. The short, highly effective and inexpensive standardized MDR-TB treatment will improve patient’s compliance. Thus a patient benefit is there. TB STUDY GROUP (TSG) congratulates Armand Van Deun for his initiative to carry out such a research with short, highly effective and inexpensive standardized MDR-TB treatment. TSG also congratulates him for receiving the Kochon prize for 2010. Van Deon is a great friend of TB patients of Bangladesh. TSG sincerely appreciates his effort in the field of Tuberculosis. Dr. Ahmed Parvez Zabeen Chief Executive Office TB STUDY GROUP (TSG) Short, highly effective and inexpensive standardized treatment for MDT-TB

Tuberculosis is a major public health problem in Bangladesh as well as the MDR-TB. Bangladesh is a resource constrains country. MDR-TB treatment facilities are inadequate. A long ques for MDR-TB patients are seen each year; WHO recommended conventional treatment needs 18 months to 24 months to be completed.

Short, highly effective and inexpensive standardized treatment for MDT-TB requires only 9 (nine) months in some case few more months are necessary with modification of combination of second and first line drugs from conventional treatment.

The research results has shown that treatment outcome is as like as the treatment outcome of first line drugs (for the Tuberculosis). The result is encouraging and it definitely improves compliance of MDT-TB patients. The compliance of standardized MDR-TB drugs is a big issue due to its long duration. The short, highly effective and inexpensive standardized MDR-TB treatment will improve patient’s compliance. Thus a patient benefit is there.

TB STUDY GROUP (TSG) congratulates Armand Van Deun for his initiative to carry out such a research with short, highly effective and inexpensive standardized MDR-TB treatment.

TSG also congratulates him for receiving the Kochon prize for 2010.
Van Deon is a great friend of TB patients of Bangladesh. TSG sincerely appreciates his effort in the field of Tuberculosis.

Dr. Ahmed Parvez Zabeen
Chief Executive Office
TB STUDY GROUP (TSG)

]]> Comment on FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval by Aung http://www.newtbdrugs.org/blog/fda-advisory-committee-recommends-janssens-bedaquiline-for-accelerated-approval/comment-page-1/#comment-6637 Aung Wed, 19 Dec 2012 06:43:31 +0000 http://www.newtbdrugs.org/blog/?p=4213#comment-6637 Bedaquiline is an excellent drug for XDR TB cases. So it might be more potent for MDR TB cases. We need this drug to shorten MDR TB regimen. Bedaquiline is an excellent drug for XDR TB cases. So it might be more potent for MDR TB cases. We need this drug to shorten MDR TB regimen.

]]> Comment on FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval by Working Group http://www.newtbdrugs.org/blog/fda-advisory-committee-recommends-janssens-bedaquiline-for-accelerated-approval/comment-page-1/#comment-6545 Working Group Tue, 04 Dec 2012 17:04:37 +0000 http://www.newtbdrugs.org/blog/?p=4213#comment-6545 Taken from Janssen's presentation at the FDA Anti-infective Advisory Committee Meeting on Nov. 28, Bedaquiline was tested with a 5-drug background regimen consisting of ethionamide, pyrazinamide, ofloxacin, kanamycin and terizidone/cycloserine. This background regimen could be adjusted due to drug sensitivity test results and side effects. Any switches in drugs were within the same drug class. Taken from Janssen’s presentation at the FDA Anti-infective Advisory Committee Meeting on Nov. 28, Bedaquiline was tested with a 5-drug background regimen consisting of ethionamide, pyrazinamide, ofloxacin, kanamycin and terizidone/cycloserine. This background regimen could be adjusted due to drug sensitivity test results and side effects. Any switches in drugs were within the same drug class.

]]> Comment on FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval by Patricia G. Nelson http://www.newtbdrugs.org/blog/fda-advisory-committee-recommends-janssens-bedaquiline-for-accelerated-approval/comment-page-1/#comment-6544 Patricia G. Nelson Tue, 04 Dec 2012 15:07:17 +0000 http://www.newtbdrugs.org/blog/?p=4213#comment-6544 Which drugs were tested with the bedaquiline, since it is to be used in combination therapy? Which drugs were tested with the bedaquiline, since it is to be used in combination therapy?

]]> Comment on FDA Advisory Committee recommends Janssen’s Bedaquiline for accelerated approval by Patricia G. Nelson http://www.newtbdrugs.org/blog/fda-advisory-committee-recommends-janssens-bedaquiline-for-accelerated-approval/comment-page-1/#comment-6543 Patricia G. Nelson Tue, 04 Dec 2012 15:06:42 +0000 http://www.newtbdrugs.org/blog/?p=4213#comment-6543 What drugs was the bedaquiline tested with, since it is proposed to be used in combination therapy? What drugs was the bedaquiline tested with, since it is proposed to be used in combination therapy?

]]> Comment on Working Group on New TB Drugs Launches Strategic Plan 2011-2015 by Nelly Solomonia http://www.newtbdrugs.org/blog/working-group-on-new-tb-drugs-launches-strategic-plan-2011-2015/comment-page-1/#comment-6402 Nelly Solomonia Fri, 12 Oct 2012 13:55:38 +0000 http://www.newtbdrugs.org/blog/?p=3680#comment-6402 One of the objective of the Strategic Plan is to build capacity for new sites of clinical trials and it's very important. Involvement of high TB burden countries in this process will give opportunity to make real conclusions and recommendations. Hope, WGND will ensure to find good partners in countries. Sure, representatives from national TB programs will support clinical trials. With kind regards, Nelly Solomonia One of the objective of the Strategic Plan is to build capacity for new sites of clinical trials and it’s very important. Involvement of high TB burden countries in this process will give opportunity to make real conclusions and recommendations. Hope, WGND will ensure to find good partners in countries. Sure, representatives from national TB programs will support clinical trials.

With kind regards,

Nelly Solomonia

]]> Comment on InTB Winners Announced! by Patrick Ogwok http://www.newtbdrugs.org/blog/intb-winners-announced/comment-page-1/#comment-6156 Patrick Ogwok Sun, 05 Aug 2012 16:44:14 +0000 http://www.newtbdrugs.org/blog/?p=4026#comment-6156 The competetion itself is a very new innovation that encourages good ideas to be generated. I am very certain that people will continue innovating until TB is completely controlled. The competetion itself is a very new innovation that encourages good ideas to be generated. I am very certain that people will continue innovating until TB is completely controlled.

]]> Comment on Welcome to Innovate TB! by SLF are TB Advocay Winners – - Sustainable Livelihoods FoundationSustainable Livelihoods Foundation http://www.newtbdrugs.org/blog/innovatetb/comment-page-1/#comment-5581 SLF are TB Advocay Winners – - Sustainable Livelihoods FoundationSustainable Livelihoods Foundation Tue, 10 Jul 2012 09:20:12 +0000 http://www.newtbdrugs.org/blog/?page_id=3582#comment-5581 [...] for Health Group, is the inaugural Advocacy Winner of the Stop TB Partnership Innovative TB contest http://www.newtbdrugs.org/blog/innovatetb/SLF were chosen as winners due to their popularity with the voters and judging by a panel of experts [...] [...] for Health Group, is the inaugural Advocacy Winner of the Stop TB Partnership Innovative TB contest http://www.newtbdrugs.org/blog/innovatetb/SLF were chosen as winners due to their popularity with the voters and judging by a panel of experts [...]

]]> Comment on Welcome to Innovate TB! by Contesting TB « lillycoi http://www.newtbdrugs.org/blog/innovatetb/comment-page-1/#comment-4043 Contesting TB « lillycoi Thu, 24 May 2012 18:55:24 +0000 http://www.newtbdrugs.org/blog/?page_id=3582#comment-4043 [...] nod to the Stop TB Partnership and it’s New Drug Working Group, who have put together the Innovate TB (inTB) Contest.  inTB gathers videos, photos and write-ups that tell stories of innovation focused on the fight [...] [...] nod to the Stop TB Partnership and it’s New Drug Working Group, who have put together the Innovate TB (inTB) Contest.  inTB gathers videos, photos and write-ups that tell stories of innovation focused on the fight [...]

]]>